Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy
Autor: | Aman U. Buzdar, Frankie A. Holmes, Giuseppe Fraschini, Marsha D. McNeese, Frederick C. Ames, S. Eva Singletary, Shu‐Wan ‐W Kau, Gabriel N. Hortobagyi, Richard L. Theriault, Verena Hug |
---|---|
Rok vydání: | 1992 |
Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Mammary gland medicine.disease Surgery medicine.anatomical_structure Breast cancer Oncology Internal medicine medicine Adjuvant therapy Stage (cooking) business Complication Estrogen Receptor Status Survival rate |
Zdroj: | Cancer. 69:448-452 |
ISSN: | 1097-0142 0008-543X |
DOI: | 10.1002/1097-0142(19920115)69:2<448::aid-cncr2820690229>3.0.co;2-k |
Popis: | Between 1974 and 1986, 283 patients with ten or more positive nodes were treated in four prospective trials using doxorubicin-containing adjuvant chemotherapy. At a median follow-up of 92 months, 182 patients had had a recurrence, and 158 died. An estimated 41% and 37% were disease-free at 5 and 7 years, respectively. Patients with ten positive nodes had a significantly better disease-free survival than those with more than ten such nodes (P = 0.04). The disease-free survival rate and overall survival rate were not influenced by the estrogen receptor status of the tumor, patient age, or disease stage. Long-term data on a large number of patients treated at this institute showed the natural history of this subgroup of patients. Approximately 30% of patient survived disease-free at 10 years after treatment with the systemic therapies used in these protocols. Newer approaches are needed to alter the prognosis of this subgroup of patients further. |
Databáze: | OpenAIRE |
Externí odkaz: |